Dexcom is hoping to win FDA approval to begin selling its G7 continuous glucose monitor in the U.S. later this year. (Shown here with an Apple Watch). · MedTech Dive · Courtesy of Dexcom A warning ...
StockStory.org on MSN
DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results